Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.03
OPK's Cash to Debt is ranked higher than
64% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. OPK: 1.03 )
OPK' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 1.03

Equity to Asset 0.69
OPK's Equity to Asset is ranked higher than
76% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. OPK: 0.69 )
OPK' s 10-Year Equity to Asset Range
Min: -0.41   Max: 0.96
Current: 0.69

-0.41
0.96
F-Score: 2
Z-Score: 4.52
M-Score: -2.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -137.73
OPK's Operating margin (%) is ranked lower than
53% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. OPK: -137.73 )
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44   Max: -39.08
Current: -137.73

-31624.44
-39.08
Net-margin (%) -168.47
OPK's Net-margin (%) is ranked lower than
54% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. OPK: -168.47 )
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54   Max: -4.59
Current: -168.47

-44561.54
-4.59
ROE (%) -19.25
OPK's ROE (%) is ranked higher than
55% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. OPK: -19.25 )
OPK' s 10-Year ROE (%) Range
Min: -3194.35   Max: -1.4
Current: -19.25

-3194.35
-1.4
ROA (%) -12.04
OPK's ROA (%) is ranked higher than
55% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. OPK: -12.04 )
OPK' s 10-Year ROA (%) Range
Min: -1352.71   Max: -0.83
Current: -12.04

-1352.71
-0.83
ROC (Joel Greenblatt) (%) -562.31
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.36 vs. OPK: -562.31 )
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130662.93   Max: -57.21
Current: -562.31

-130662.93
-57.21
Revenue Growth (%) 34.90
OPK's Revenue Growth (%) is ranked higher than
97% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. OPK: 34.90 )
OPK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 135.1
Current: 34.9

0
135.1
EBITDA Growth (%) 91.30
OPK's EBITDA Growth (%) is ranked higher than
99% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. OPK: 91.30 )
OPK' s 10-Year EBITDA Growth (%) Range
Min: -75.7   Max: 171.4
Current: 91.3

-75.7
171.4
EPS Growth (%) 74.70
OPK's EPS Growth (%) is ranked higher than
99% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. OPK: 74.70 )
OPK' s 10-Year EPS Growth (%) Range
Min: -69.4   Max: 152.4
Current: 74.7

-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OPK Guru Trades in Q3 2013

Jim Simons 17,802 sh (New)
George Soros 745,000 sh (New)
Steven Cohen 29,200 sh (New)
Murray Stahl 79,305 sh (+77.42%)
Mario Gabelli 15,000 sh (unchged)
» More
Q4 2013

OPK Guru Trades in Q4 2013

Steven Cohen 46,194 sh (+58.2%)
Murray Stahl 97,806 sh (+23.33%)
George Soros 844,600 sh (+13.37%)
Mario Gabelli 15,000 sh (unchged)
Jim Simons Sold Out
» More
Q1 2014

OPK Guru Trades in Q1 2014

Paul Tudor Jones 12,253 sh (New)
George Soros 1,494,800 sh (+76.98%)
Murray Stahl 123,170 sh (+25.93%)
Mario Gabelli 15,000 sh (unchged)
Steven Cohen Sold Out
» More
Q2 2014

OPK Guru Trades in Q2 2014

Paul Tudor Jones 13,145 sh (+7.28%)
Murray Stahl 125,930 sh (+2.24%)
Mario Gabelli 15,000 sh (unchged)
George Soros 235,600 sh (-84.24%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Reduce -84.24%0.12%$8.01 - $9.71 $ 8.4-4%235600
George Soros 2014-03-31 Add 76.98%0.06%$7.58 - $9.96 $ 8.4-4%1494800
George Soros 2013-09-30 New Buy0.07%$7.18 - $9.24 $ 8.45%745000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

OPKO CEO Is Building A Pharma Powerhouse And Continuously Buying Shares
OPKO Health (OPK) has come to my attention because I noticed that the chairman and CEO, Dr. Phillip Frost, has been consistently showing up on the list of CEO buys at GuruFocus. As I look back at the history, he has been doing so for years. According to the Form 4 filed with the SEC, his is the beneficial owner of shares in his own name, his trust, and an LLC. Together he is the beneficial owner of 158.71 million out of the 412.91 million shares outstanding, representing about 38 percent of the shares. As of 6/19/14, his position is valued at $1.457 billion. Phillip Frost has had many successful investments in the past, could this be the next one? Read more...
Weekly CEO Buys Highlight: OPK, PAYC, CLMS, WINA, HBAN
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, AMRC, ENBL, ALLY, NEON
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, AMRC, CLMS, OILT, WMC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: KCG, OPK, HOLX, CLMS, TDC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, GE, CLMS, HELI, GAM
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, HELI, RSPP, CLMS
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 3.91
OPK's P/B is ranked higher than
56% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. OPK: 3.91 )
OPK' s 10-Year P/B Range
Min: 3.65   Max: 50.6
Current: 3.91

3.65
50.6
P/S 38.18
OPK's P/S is ranked lower than
67% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. OPK: 38.18 )
OPK' s 10-Year P/S Range
Min: 15.25   Max: 126.5
Current: 38.18

15.25
126.5
EV-to-EBIT -29.97
OPK's EV-to-EBIT is ranked higher than
58% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 35.63 vs. OPK: -29.97 )
OPK' s 10-Year EV-to-EBIT Range
Min: -107   Max: -3.8
Current: -29.97

-107
-3.8
Current Ratio 2.30
OPK's Current Ratio is ranked higher than
66% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. OPK: 2.30 )
OPK' s 10-Year Current Ratio Range
Min: 0.88   Max: 415
Current: 2.3

0.88
415
Quick Ratio 2.07
OPK's Quick Ratio is ranked higher than
72% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. OPK: 2.07 )
OPK' s 10-Year Quick Ratio Range
Min: 0.48   Max: 415
Current: 2.07

0.48
415

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 16.80
OPK's Price/DCF (Projected) is ranked higher than
64% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 28.60 vs. OPK: 16.80 )
OPK' s 10-Year Price/DCF (Projected) Range
Min: 7.22   Max: 236.67
Current: 16.8

7.22
236.67
Price/Median PS Value 1.12
OPK's Price/Median PS Value is ranked higher than
65% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. OPK: 1.12 )
OPK' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 10.05
Current: 1.12

0.27
10.05
Earnings Yield (Greenblatt) -3.30
OPK's Earnings Yield (Greenblatt) is ranked lower than
99% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. OPK: -3.30 )
OPK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -3.3

Forward Rate of Return (Yacktman) 28.19
OPK's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. OPK: 28.19 )
OPK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -30   Max: 28.1
Current: 28.19

-30
28.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico
Opko Health, Inc. was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc., which was later changed to eXegenics, Inc. On June 8, 2007, the Company changed its name to OPKO Health, Inc. It is a biopharmaceutical and diagnostics company, which is focused on the discovery, development, and commercialization of proprietary pharmaceuticals, diagnostic and imaging systems and instrumentation products for the treatment, diagnosis and management of ophthalmic diseases and conditions. The Company's business presently consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. The Company operates a U.S.-based laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, as amended ("CLIA"), with a urologic focus that it expects will serve as a commercial platform for the U.S. launch of OPKO's next generation test for the early detection of prostate cancer. In addition, it operates a specialty active pharmaceutical ingredients ("APIs") manufacturer in Israel, which it expects will play a valuable role in the development of its pipeline of molecules and compounds for their proprietary molecular diagnostic and therapeutic products. It continues to actively explore opportunities to acquire complementary pharmaceuticals, compounds, technologies, and businesses. In late 2011, it acquired a novel diagnostic instrument system that provides rapid, high performance blood test results and enables complex tests to be run in point-of-care settings. The Company faces competition from competitors for its instrumentation products located in the United States and abroad, which competitors include companies with a far more diverse product offering and greater market presence than its, such as Carl Zeiss Meditec, Topcon Corporation, and Heidelberg Engineering, as well as a number of smaller competitors and smaller start-up companies that might also have competing technologies and products. The Company is also subject to various federal, state, and international laws pertaining to health care 'fraud and abuse,' including anti-kickback laws and false claims laws.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Weekly CEO Buys Highlight: NRP, SFXE, OPK, EPE, OMN Oct 12 2014 
Highlight of This Week's Insider Buys Sep 30 2014 
Weekly CEO Buys Highlight: CREG, OPK, LDOS, HALL, ULTA Sep 21 2014 
Weekly CEO Buys Highlight: TITN, OPK, LDOS, FSFR, BRX Sep 16 2014 
Weekly CEO Buys Highlight: OPK, BOBE, CONN, WPX, PHII Sep 08 2014 
Weekly CEO Buys Highlight: TDG, OPK, QNST, PVA, CIO Sep 02 2014 
Weekly CEO Buys Highlight: FSFR, FSIC, OPK, EPE, ACXM Aug 23 2014 
Weekly CEO Buys Highlight: FSIC, NLY, OPK, GPC, ACXM Aug 17 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

More From Other Websites
Cocrystal Pharma Develops Novel Ebola Screening Technology Oct 23 2014
Neovasc, an OPKO Investee, Receives FDA Conditional Approval to Initiate TIARA-I Trial in U.S.: A... Oct 09 2014
Mazor Robotics Ltd. (MZOR) in Focus: Stock Soars 11.3% Oct 07 2014
OPKO Health Supports National Prostate Cancer Council Legislation Sep 29 2014
OPKO Health (OPK) Reports Positive Data on Rayaldee Trial Sep 24 2014
OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints Sep 23 2014
OPKO Launches the 4Kscore Test in Europe Sep 15 2014
Opko (OPK) Sees Hammer Chart Pattern: Time to Buy? Sep 12 2014
Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be... Sep 11 2014
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant Sep 09 2014
OPKO Licensee TESARO Submits New Drug Application for Rolapitant Sep 08 2014
OPKO HEALTH, INC. Financials Aug 19 2014
'Mad Money' Lightning Round: Don't Buy IBM Right Now Aug 14 2014
Opko’s Frost Discusses Treatment of Kidney Disease (Audio) Aug 13 2014
Taking Stock: Manley on Markets, Frost on Biotech (Audio) Aug 12 2014
Taking Stock: Manley on Markets, Frost on Biotech Aug 12 2014
OPKO HEALTH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 12 2014
OPKO HEALTH, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
OPKO Announces Second Quarter Operating and Financial Results Aug 11 2014
Rayaldee Phase 3 Trial Meets Primary Endpoints Aug 11 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK